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Molecular changes during extended
neoadjuvant letrozole treatment of breast
cancer: distinguishing acquired resistance
from dormant tumours
Cigdem Selli1,2, Arran K. Turnbull1,3, Dominic A. Pearce1, Ang Li1, Anu Fernando1,3, Jimi Wills4, Lorna Renshaw3,
Jeremy S. Thomas3, J. Michael Dixon3 and Andrew H. Sims1*
Abstract
Background: The risk of recurrence for endocrine-treated breast cancer patients persists for many years or even decades
following surgery and apparently successful adjuvant therapy. This period of dormancy and acquired resistance is inherently
difficult to investigate; previous efforts have been limited to in-vitro or in-vivo approaches. In this study, sequential tumour
samples from patients receiving extended neoadjuvant aromatase inhibitor therapy were characterised as a novel clinical
model.
Methods: Consecutive tumour samples from 62 patients undergoing extended (4–45months) neoadjuvant aromatase
inhibitor therapy with letrozole were subjected to transcriptomic and proteomic analysis, representing before (≤ 0), early
(13–120 days), and long-term (> 120 days) neoadjuvant aromatase inhibitor therapy with letrozole. Patients with at least a
40% initial reduction in tumour size by 4months of treatment were included. Of these, 42 patients with no subsequent
progression were classified as “dormant”, and the remaining 20 patients as “acquired resistant”.
Results: Changes in gene expression in dormant tumours begin early and become more pronounced at later time
points. Therapy-induced changes in resistant tumours were common features of treatment, rather than being specific
to the resistant phenotype. Comparative analysis of long-term treated dormant and resistant tumours highlighted
changes in epigenetics pathways including DNA methylation and histone acetylation. The DNA methylation marks 5-
methylcytosine and 5-hydroxymethylcytosine were significantly reduced in resistant tumours compared with dormant
tissues after extended letrozole treatment.
Conclusions: This is the first patient-matched gene expression study investigating long-term aromatase inhibitor-
induced dormancy and acquired resistance in breast cancer. Dormant tumours continue to change during treatment
whereas acquired resistant tumours more closely resemble their diagnostic samples. Global loss of DNA methylation
was observed in resistant tumours under extended treatment. Epigenetic alterations may lead to escape from
dormancy and drive acquired resistance in a subset of patients, supporting a potential role for therapy targeted at
these epigenetic alterations in the management of resistance to oestrogen deprivation therapy.
Keywords: Dormancy, Oestrogen deprivation therapy, Epigenetics, Letrozole, Sequential samples, Resistance,
Microarray, Proteomics
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Background
Approximately 70% of breast cancer patients who have
oestrogen receptor (ER) alpha-positive tumours receive
adjuvant oestrogen deprivation therapy. Five years of
aromatase inhibitor therapy produces a 40% reduction in
10-year mortality [1]. However, while the annual risk of
mortality for ER-negative breast cancer decreases follow-
ing the first 5 years after diagnosis, the annual rate re-
mains constant for ER+ patients [2]. In fact, women with
ER+ early-stage disease treated with 5 years of adjuvant
endocrine therapy have a persistent risk of recurrence
and death from breast cancer for at least 20 years after
diagnosis [3]. Molecular studies have demonstrated that
nodal and distant metastases are highly similar to their
matched primary tumours, implicating a continuation of
the original cancer [4–6]. However, the time between
treatment and recurrence is often greater than that
which can be explained by normal cell-doubling rates
[7], implying cancer cells remain dormant in the body
before re-awakening.
Residual dormant cancer cells are hypothesised to per-
sist either by withdrawing from the cell cycle and transi-
tioning to a quiescence state or by continuing to
proliferate at a reduced rate, counter-balanced by cell
death [8]. Reawakened dormant cells may become de-
tectable after reaching a detection threshold or reacti-
vated via increased angiogenesis, and/or escape from the
inhibitory microenvironment or immune effects [9, 10].
Dormancy is therefore considered a major mechanism
underlying resistance to therapy, where dormant cells
survive despite anti-proliferative oestrogen deprivation
therapy.
Resistance to oestrogen deprivation therapy may occur
at disease inception (de novo or innate resistance), but a
larger proportion of patients acquire resistance during
treatment (acquired/secondary resistance) [11]. Several
mechanisms of resistance to oestrogen deprivation ther-
apy have been described previously [12, 13]. However,
the majority of these findings are based on preclinical
data obtained from cell lines and animal models. It is
therefore difficult to know if these accurately reflect mo-
lecular changes in patient tumours.
Expression profiling of clinical samples, measuring the
effect of, or predicting response to, treatment has re-
cently become feasible. However, experimental design is-
sues, such as the difficulty in obtaining paired samples
for comparison, particularly for longer time intervals,
makes it difficult to study changes within tumours [14].
For example, a previous study investigating tamoxifen
failure compared samples from patients requiring sal-
vage surgery with pre-treatment samples from an unre-
lated group of disease-free patients [15]. More recently,
sequential patient-matched samples have been success-
fully utilised to determine treatment-induced dynamic
changes in tumours at 2 weeks to 3 months, demonstrat-
ing the effectiveness of this approach [16–18].
For a variety of reasons, including being unfit for sur-
gery, a proportion of patients receiving pre-surgical
oestrogen deprivation therapy do not have their tumours
excised following 3–4 months of treatment. These
long-term endocrine-treated tumours represent a unique
group that can inform how tumours respond to ex-
tended oestrogen deprivation in situ. Having initially
shrunk in size, some tumours remain at a steady volume
and appear dormant, whilst others subsequently begin to
regrow. We have utilised this unique cohort of sequen-
tial samples from patients receiving extended neoadju-
vant oestrogen deprivation therapy to characterise
luminal breast cancer dormancy and acquired resistance
as a novel clinical model.
Methods
Patients and samples
Breast cancer patients were treated with neoadjuvant
aromatase inhibitor therapy with letrozole (Femara, 2.5
mg; Novartis Pharma AG, Basel, Switzerland) for a mini-
mum of 4 months; tumours were not removed either be-
cause patients declined or were unfit for surgery. The
study was approved by the local regional ethics commit-
tee (07/S1103/26, August 2007) and all patients gave in-
formed consent. Clinical characteristics of the tumours
are given in Table 1. A consort diagram detailing inclu-
sion and exclusion criteria is provided in Additional file 1
(Figure S1). Patients with > 40% initial decrease in
tumour size by 4months of treatment were included in
the study. Those with no subsequent progression on im-
aging by the latest biopsy were classified as “dormant”;
otherwise, they were classified as “acquired resistant”
(Fig. 1a, b). For patients whose latest ultrasound scan
(USS) measurement was taken more than a month be-
fore surgery, changes in gene expression (mean relative
change) of three widely used proliferation markers
(MKI67, PCNA, and MCM2) were used to assist classifi-
cation. Tumours with an increase in proliferation marker
expression (either after an initial decrease or not) were
classified as “acquired resistant”, otherwise there were
classified as “dormant”. Sequential tumour biopsies were
taken with a 14-gauge needle before and after letrozole
treatment and at the time of surgery. Fresh samples were
snap-frozen in liquid nitrogen and each tumour sample
was confirmed to contain ≥ 50% cellularity and at least
60% tumour tissue using haematoxylin and eosin (H&E)
sections. Following pulverisation of tissue with a mem-
brane disruptor (Micro-Dismembrator U, Braun Bio-
tech), phase separation was performed by guanidinium
thiocyanate-phenol-chloroform extraction (Qiazol Lysis
Reagent).
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Table 1 Patient characteristics
Dormant, n (%) Resistant, n (%) Total, n p valuea
Total no. of patients 42 20 62
Total no. of samples 111 56 167
Age at diagnosis
Mean 75 72
Range 53–87 56–89
Tumour grade 0.39
1 6 (14.3) 1 (5.0) 7
2 27 (64.3) 10 (50.0) 37
3 8 (19.0) 6 (30.0) 14
NA 1 (2.4) 3 (15.0) 4
Tumour size 0.71
T1 5 (11.9) 4 (20.0) 9
T2 19 (45.2) 9 (45.0) 28
T3 2 (4.8) 2 (10.0) 4
T4 11 (26.2) 4 (20.0) 15
NA 5 (11.9) 1 (5.0) 6
Nodal status 0.36
N0 27 (64.3) 11 (55.0) 38
N1 8 (19.0) 7 (35.0) 15
N2 1 (2.4) 1 (5.0) 2
N3 1 (2.4) 0 1
NX 1 (2.4) 0 1
NA 4 (9.5) 1 (5.0) 5
Metastasis status 1.00
M0 34 (80.9) 18 (90.0) 56
M1 2 (4.8) 0 2
MX 1 (2.4) 1 (5.0) 2
NA 5 (11.9) 1 (5.0) 6
ER score (Allred) 0.18
6 1 (2.4) 0 1
7 6 (14.3) 6 (30.0) 12
8 35 (83.3) 14 (70.0) 49
HER status 0.69
Negative 35 (83.3) 12 (60.0) 47
Positive 6 (14.3) 3 (15.0) 9
NA 1 (2.4) 5 (25.0) 6
Histological type 0.73
IDC (no special type) 18 (42.9) 6 (30) 24
ILC 8 (19.0) 4 (20) 12
Mucinous 1 (2.4) 0 1
NA 15 (35.7) 10 (50) 25
Molecular subtypeb 1.00
Luminal A 21 (50.0) 9 (45.0) 30
Luminal B 20 (47.6) 9 (45.0) 29
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Gene expression profiling and analysis
RNA was extracted from the aqueous phase by
column-based purification (RNeasy mini kit, Qiagen)
and then labelled and hybridized (HumanHT-12 v4 Illu-
mina BeadChip) according to the manufacturer’s proto-
col (NuGEN) as previously described [19, 20]. Raw data
were detection (p < 0.05, ≥ 3 samples) and quality fil-
tered, log2 transformed, and quantile normalized using
the Bioconductor lumi package [21]. Data are publicly
available from NCBI GEO under accession GSE111563.
The analysis also includes data from 14 patients (42
samples, GSE59515) and 9 patients (24 samples,
GSE55374) from previous studies [16, 19] which meet
the criteria defined above; the relationship between the
samples from these datasets is indicated in Add-
itional file 2 (Table S1). Hierarchical clustering analysis
was performed using a complete linkage method and
Euclidean distance. Pathway enrichment analysis and
visualisation were performed using ReactomePA [22].
Differential gene expression analysis was performed with
Rank Products [23]. The significance of differences was
evaluated by using unpaired Wilcoxon test for two
groups and analysis of variance (ANOVA) with post-hoc
Tukey HSD for multiple comparisons.
Proteomics analysis
Proteins were isolated from the organic phase of Qiazol
[24]. Pellets were sonicated and dissolved in 1% SDS.
Proteomics was performed using Thermo Q Exactive
plus and Label-free Quantitation (LFQ). Peptides ob-
tained from samples were analysed in mass spectrometry
runs; serial samples from the patients were run on the
same day. A modified version of Filter Aided Sample
Preparation (FASP) was performed using serial digests
with lysC and trypsin to generate two orthogonal frac-
tions per sample [25, 26]. The mass spectrometry spec-
tra generated in each run were used for relative
quantitation of individual peptides. Normalization and
quantifications of peptides were performed using
MaxLFQ and MaxQuant [27]. A total of 6251 protein
groups were identified. Data was log2 transformed and
missing values were imputed as the minimum observed
value in each sample. The data have been deposited to
the ProteomeXchange Consortium via the PRIDE [28]
partner repository with the dataset identifier
PXD009328.
Immunohistochemistry and scoring
Formalin-fixed paraffin-embedded (FFPE) sections were
processed using an automated stainer (Leica Biosystems,
Bond III). Heat-induced epitope retrieval for both anti-
bodies was performed by 30-min incubation in
citrate-based pH 6.0 epitope retrieval (ER1) solution
followed by incubation in 3.5 N HCl for 15 min at room
temperature as suggested by Haffner et al. [29]. For
5-methylcytosine (5-mC) and 5-hydroxymethylcytosine
(5-hmC) detection, mouse monoclonal 5-methylcytosine
specific (33D3; Abcam, ab10805) and rabbit polyclonal
5-hydroxylmethylcytosine (Active Motif, 39,769) anti-
bodies were used, respectively. Both antibodies were
used at 1/1000 dilution and were incubated for 15 min.
Detection was performed using secondary
antibody-horseradish peroxidase (HRP) conjugates and
substrate-chromogen (3,3’-diaminobenzidine (DAB)).
After staining, slides were counterstained with haema-
toxylin. Nuclear staining in epithelial cells was evaluated
using an H-score obtained by multiplying the intensity
of the stain (0: no staining; 1: weak staining; 2: moderate
staining; 3: intense staining) by the percentage of cells
(H-score range, 0 to 300).
Results
Long-term oestrogen deprivation therapy as a model of
dormancy and acquired resistance
A cohort of 62 primary breast cancer patients receiving
at least 4 months of oestrogen deprivation therapy
(Fig. 1a) and initially responding were stratified into two
groups, ‘dormant’ and ‘acquired resistant’ based on dy-
namic changes in tumour size and proliferation (see
methods and Fig. 1b). Patient-matched sequential sam-
ples were available at three time points: before (≤ 0 days),
early (13–120 days), and long-term (> 120 days) treat-
ment. Dormant and acquired resistant samples were dis-
tributed uniformly with respect to time on treatment,
and duration at each time point was not significantly dif-
ferent between response groups (Table 1). For long-term
treatment, the mean and range were 186 (121–884) days
Table 1 Patient characteristics (Continued)
Dormant, n (%) Resistant, n (%) Total, n p valuea
HER2 enriched 0 1 (5.0) 1
Basal-like 0 0 0
Normal-like 0 0 0
NA 1 (2.4) 1 (5.0) 2
ER oestrogen receptor, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, NA not available
aFisher exact test (p < 0.05, two-tailed)
bAt diagnosis by PAM50 (genefu)
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Fig. 1 (See legend on next page.)
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and 226 (121–1366) days for patients with dormant and
acquired resistant tumours, respectively (Fig. 1c).
There were no significant differences in patient
clinico-pathological features between response classes
before treatment (Table 1). However, prediction ana-
lysis of microarray (PAM)50 intrinsic molecular sub-
types were found to change during oestrogen
deprivation therapy (Fig. 1d). These changes were
consistent with known associations with outcome,
with all dormant tumours either remaining the same
or switching to better prognosis luminal A or
normal-like tumours. For resistant tumours, however,
25% (5 out of 20) switched to a subtype of worse
prognosis (Fig. 1d). The proportion of luminal B tu-
mours characterised by reduced endocrine sensitivity
and higher proliferation was higher in resistant tu-
mours compared with dormant tumours under early
(35% versus 27%) and long-term (50% versus 12%)
treatment (Fig. 1d; stacked bar graphs on the right).
The PAM50 defines breast cancer into four intrinsic
molecular subtypes: luminal A, luminal B, HER2-
enriched, and basal-like [30]. PAM50 intrinsic subtyp-
ing has been shown to provide additional prognostic
value to standard clinicopathological factors where lu-
minal A tumours had a significantly better outcome
than luminal B, HER2-enriched, and basal-like tu-
mours [31].
As expected, Kaplan-Meier survival analysis demon-
strated significantly worse outcomes for patients with
resistant tumours compared with patients with dor-
mant tumours (log rank, p = 0.026; Fig. 1e). Recur-
rence rates for patients with dormant and resistant
tumours were 21% (9/42) and 45% (9/20), respect-
ively. Moreover, patients with resistant tumours suf-
fered significantly earlier recurrences compared with
patients with dormant tumours (p = 0.05; range 26–
947 versus 136–2042 days; Fig. 1f ). Disease-free sur-
vival and time to recurrence were defined from time
of surgery, not from the time of diagnosis, since pa-
tient classification was performed based on change in
tumour size by USS and proliferation by gene expres-
sion at on-treatment and surgery time points.
Distinct transcriptomic changes under long-term letrozole
treatment
Unsupervised analysis was performed to consider
whether sequential samples displayed greater similarity
between response classes or treatment duration. Hier-
archical clustering using the 500 genes with the highest
variance across all samples revealed two main subclasses,
seemingly driven by time on treatment, with resistant
and dormant tumours indistinguishable (Fig. 2a). The
dominant pattern was that the samples of the same pa-
tient usually clustered together (Fig. 2a).
When long-term treated samples were considered
alone, two clusters did emerge, the larger of which con-
tained mostly dormant samples (79%), whilst the second
had a roughly even proportion of dormant (48%) and re-
sistant (52%) samples (Fig. 2a). Similarly, a multidimen-
sional scaling (MDS) plot for the 500 genes with the
highest variance across all time points revealed consist-
ent changes over time in response to treatment for both
dormant and acquired resistant samples (Fig. 2b), al-
though long-term dormant samples were much more
distinguishable from pre-treatment samples than the
long-term acquired resistant samples (Fig. 2b).
Correlations between tumours from different individ-
uals (inter-patient) remained similar at each time point
and were not different between response classes (data
not shown) as corroborated by hierarchical clustering
analysis with all samples and across all the time points.
However, correlations of the transcriptome between
matched sequential samples (intra-patient) revealed that
pre-treatment samples were significantly (p = 0.01) less
similar to their long-term treated pairs (median 0.89,
range 0.74–0.95) than their early treatment pairs (me-
dian 0.91, range 0.84–0.95) (Fig. 2c). However, when di-
vided by dormancy status this finding was only
significant (p = 0.01) for dormant tumours (Fig. 2c), sug-
gesting that dormant tumours continue to diverge tran-
scriptionally whereas acquired resistant tumours do not
consistently differ after initial or extended treatment, as
mirrored in the MDS representation (Fig. 2b).
Perhaps surprisingly, oestrogen, progesterone, and an-
drogen receptors and their target genes [32] were not
(See figure on previous page.)
Fig. 1 Long-term oestrogen deprivation therapy as a clinical model to investigate breast cancer dormancy and acquired resistance. a Extended (4–45months)
letrozole treatment was exploited as a clinical model of breast cancer dormancy and acquired resistance. Sequential clinical samples from the same patient
with no surgery and extended treatment were used to model clinical breast cancer dormancy and resistance. Before (pre, ≤ 0 days), early-on (early, 13–120
days) and long-term (long, > 120 days) neoadjuvant aromatase inhibitor therapy with letrozole. b Dynamic change in tumour size by ultrasound scan (USS) and
mean expression of proliferation markers MKI67, PCNA, and MCM2 were used to classify patients into two categories: dormant (blue) and resistant (red). Overall
comparisons of classifications per patient based on USS and mean change in proliferation markers with final classification are shown. c The duration of letrozole
treatment (days) for samples from dormant (blue) and resistant (red) patients. Each bar represents a sample. Samples are ordered by time on treatment. d
Intrinsic subtype classification by PAM50 of samples at each time point. Stacked bar graphs on the right show the percentage of each subtype of samples from
dormant and resistant patients. e Kaplan-Meier plot showing disease-free survival probability in patients with dormant versus resistant tumours (log-rank test).
Disease-free survival was defined from time of surgery. f Density plot showing the distribution of time to recurrence (in years; defined from time of surgery) in
patients with dormant and resistant tumours. CI confidence interval, HR hazard ratio, LumA luminal A, LumB luminal B
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differentially expressed between long-term treated dor-
mant and resistant tumours (data not shown).
Changes in gene expression/pathways following long-
term letrozole treatment
To consider whether the gene expression changes due to
treatment in the dormant and acquired resistant tumours
were the same or distinct we initially considered them
separately. Pairwise rank product analysis (pre- versus
long-term treatment, false discovery rate (FDR) < 0.01)
identified 2319 genes significantly differentially expressed
(1063 downregulated and 1256 upregulated) between
long-term treated and pre-treatment dormant tumours
(Additional file 2: Table S2). These genes were significantly
enriched (p < 0.01) for a total of 62 and 26 pathways, re-
spectively (Additional file 2: Table S3), including reduc-
tions in cell cycle, senescence, DNA methylation, and an
increase in extracellular matrix (ECM) organization. These
findings are consistent with previous studies of
patient-matched sequential samples treated with
Fig. 2 Distinct transcriptomic changes during long-term aromatase inhibitor treatment. a Unsupervised hierarchical clustering with most variant 500
genes across all samples and long-term treated samples. ER6, ER7, ER8 correspond to oestrogen receptor (ER) Allred scores 6, 7, and 8, respectively. b
Multidimensional scaling (MDS) plot using the 500 genes with the highest variance across all time points. Each dot corresponds to a sample and sizes
represent the duration of treatment. c Intra-patient (comparison of samples from the same patient) correlations of transcriptome are shown. Dormant
(blue); resistant (red); before (pre, ≤ 0 days), early-on (early, 13–120 days), and long-term (long, > 120 days) neoadjuvant aromatase inhibitor therapy
with letrozole. ***p < 0.001; **p < 0.01; *p < 0.05. NA not available, Rec+ recurrence, Rec– recurrence free
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oestrogen deprivation therapy [16–18]. Acquired resistant
tumours displayed much fewer consistently differentially
expressed genes (238; 63 downregulated and 175 upregu-
lated) between long-term treated and pre-treatment sam-
ples (Additional file 2: Table S4). Genes that were
upregulated in resistant tumours (pre-treatment versus
long-term treatment) were enriched for several of the
same pathways as dormant tumours (ECM organization,
elastic fibre formation, and platelet degranulation), but
downregulated genes were much more variable
(Additional file 2: Table S5; Fig. 3a, b).
Having determined that dormant and acquired resist-
ant tumours have somewhat distinct changes during
treatment at the molecular level, the question remained
as to whether these changes tend to occur at earlier time
points or were specific to long-term treatment. For dor-
mant tumours, differential expression begins early on,
but becomes more pronounced at later time points
(Fig. 3a). Downregulated genes (pre-treatment versus
long-term treatment) were most evident at early-on
treatment for resistant tumours, consistent with their
initial response to treatment, whilst upregulated genes
(pre-treatment versus long-term treatment) were most
changed after long-term treatment, potentially suggest-
ing that these genes may mediate acquired resistance
(Fig. 3b). We further examined whether differentially
expressed genes between pre-treatment versus
long-term treatment identified in each response class
(dormant and resistant) were shared (Fig. 3c, d). Both
downregulated and upregulated genes identified in re-
sistant tumours were significantly changed (p < 0.01) in
dormant tumours (Fig. 3d). However, only upregulated
genes identified in dormant tumours were significantly
upregulated in resistant tumours without any change in
downregulated genes (Fig. 3c), implicating a partial lack
of response to treatment at the molecular level in ac-
quired resistance patients.
A potential role of epigenetic regulation in acquired
resistance
The above findings suggest that therapy-induced dy-
namic changes in gene expression and pathways are
common features of long-term treatment, rather than
being specific to dormant or resistant phenotypes. This
led us to perform comparative analysis of dormant and
acquired resistant tumours at the long-term time point
to identify any specific differences. Unpaired rank prod-
uct analysis (FDR < 0.01) revealed a total of 419 genes
(170 downregulated and 249 upregulated) to be differen-
tially expressed between long-term treated dormant and
resistant tumours (Additional file 2: Table S6; Fig. 4a).
These genes were significantly enriched in 27 pathways
(p < 0.05), including several epigenetics-related pathways,
including “DNA methylation”, “PRC2 methylates
histones and DNA”, “histone acetyl transferases (HATs)
acetylate histones”, and “epigenetic regulation of gene
expression”, as well as senescence and cell cycle (Add-
itional file 2: Table S7; Fig. 4b). Examination of the ex-
pression of these genes alone demonstrated that they
could partially separate dormant from the majority of re-
sistant tumours (Fig. 4c). Single-sample gene set enrich-
ment analysis (ssGSEA) [33] was performed to
quantitatively score the activity of differentially
expressed genes in every sample. The score of differen-
tially upregulated genes between long-term treated dor-
mant and resistant tumours was significantly higher in
acquired resistant compared with dormant tumours
under early treatment (p < 0.05) as well as long-term
treatment (p < 0.001) (Fig. 4d).
Our results prompted us to examine whether the changes
we observed in clinical samples were similarly changed in ex-
perimental models of resistant breast cancer cells. Oestrogen
receptor-positive MCF7 cells stably transfected with the aro-
matase gene (MCF7aro cells) and long-term
oestrogen-deprived (LTED) breast cancer cells have been
widely used to understand mechanisms of aromatase inhibi-
tor resistance in vitro. Examining two publicly available gene
expression datasets (GSE10879 and GSE10911) demon-
strated that genes differentially expressed (upregulated) be-
tween acquired resistant and dormant tumours (a total of
249) were significantly enriched in aromatase inhibitor-resist-
ant cells compared with sensitive/control cells (Fig. 5a). A
total of 211 and 174 out of 249 genes were present in
GSE10879 and GSE10911, respectively. In two out of three
in-vitro studies with dynamic gene expression data from
LTED MCF7 cells, an initial decrease in ssGSEA scores
mimicking the dormancy/responsive state was followed by a
later increase representing acquired resistance (Fig. 5b), fur-
ther validating our results and emphasizing the utility of
these in-vitro models. Interestingly, no significant difference
was observed in tamoxifen- and fulvestrant-resistant MCF7
cells compared with drug-sensitive control cells (Fig. 5c) sug-
gesting the specificity of the results to resistance to aroma-
tase inhibitor therapy.
In addition, proteomic analysis of a subset of samples
was performed which revealed differential expression in
656 proteins (279 downregulated, 377 upregulated) be-
tween long-term treated dormant and resistant tumours
(rank product; p < 0.05; n = 10; Additional file 2: Table
S8; Fig. 5d). A total of 36 features including S100P and
HIST2H3A (H3.2) overlapped between proteomics and
transcriptomics, validating the results with a different
approach.
Furthermore, differentially expressed genes were
uploaded to Enricher (ENCODE Histone modification
2015 dataset) [34] to determine histone modification
enrichment. Two H3 lysine methylation modifications
(H3K27me3 and H3K4me1) were enriched
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significantly (adjusted p = 0.0003 and p = 0.004, re-
spectively) whereas no enrichment for histone acetyl-
ation was determined.
To further validate the gene expression results, im-
munohistochemical evaluation of FFPE sections re-
vealed significantly lower global 5-mC and 5-hmC
levels in resistant tumours compared with dormant
tumours under extended treatment (Fig. 6a, b). Sig-
nificantly lower 5-hmC levels in acquired resistant
compared with dormant tumours were also observed
at early treatment (Fig. 6b), suggesting hypomethyla-
tion may be predictive of emergence from dormancy.
Fig. 3 Long-term oestrogen deprivation therapy is associated with cell cycle, senescence, epigenetic regulation, and extracellular matrix
(ECM)-associated pathways. Differentially expressed genes between pre-treatment and long-term treated dormant (a) and resistant (b)
tumours were determined. Heat-maps showing change in downregulated and upregulated gene expression in dormant (a) and
resistant (b) samples. Each column represents a sample and each row a gene. Colours are log2 mean-centred values with red
indicating high values and blue indicating low expression. Bar plots on top of heat-maps represent the time on treatment (days) for
each sample. c,d Graphs show dynamic changes in mean expression of differentially expressed genes in response classes. ***p < 0.001;
**p < 0.01; *p < 0.05
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Discussion
Understanding the mechanisms underlying the mainten-
ance of and escape from dormancy have great import-
ance considering that most cancer-related deaths are
caused by metastasis rather than the primary tumour. In
this study, we describe the first sequential
patient-matched clinical dataset of extended oestrogen
deprivation therapy in breast cancer. The results high-
light the difficulty of distinguishing dormant and resist-
ant tumours, with dynamic molecular changes of
treatment being highly similar between the groups.
However, comparative analysis revealed a set of genes
significantly upregulated in resistant tumours compared
with dormant tumours within the first months of letro-
zole treatment suggesting a predictive role for changes
in DNA methylation.
Failure to reduce proliferation after 2 weeks of
oestrogen deprivation therapy [16, 35] may well identify
patients that are innately resistant; however, acquired re-
sistance remains a greater challenge in terms of identify-
ing biomarkers and appropriate alternative or
combination therapies [36]. Many of the transcriptomic
changes identified in long-term treated dormant tu-
mours are shared by some, but not all, resistant
Fig. 4 Comparative analysis of dormant and resistant tumours. a Volcano plot showing differentially expressed genes between long-term treated
dormant and resistant tumours (dormancy versus resistance genes). Some upregulated and downregulated genes in resistant tumours are
highlighted in red and blue, respectively. b Significantly enriched pathways for dormancy versus resistance genes (p < 0.01; ReactomePA). Grey
edges connecting the nodes indicates genes shared between the nodes/pathways, and the width of the edge is scaled by the number of
common genes. Colours indicates the significance (p value) where red is a lower p value. c Heatmap showing partial separation of long-term
treated dormant and resistant samples using dormancy versus resistance genes (a total of 419; 170 downregulated and 249 upregulated genes).
Colours are log2 mean-centred values with red indicating high and blue indicating low expression. Genes are sorted by fold-change (FC) values
from most to least up/downregulated. Samples are sorted by sum expression of upregulated genes. ER6, ER7, and ER8 correspond to oestrogen
receptor (ER) Allred scores 6, 7, and 8, respectively. d Comparison of single sample gene enrichment analysis (ssGSEA) scores of dormancy versus
resistance upregulated genes between dormant and acquired resistant tumours. Dormant (blue); resistant (red); before (pre, ≤ 0 days), early-on
(early, 13–120 days) and long-term (long, > 120 days) neoadjuvant aromatase inhibitor therapy with letrozole. ***p < 0.001; *p < 0.05. NA not
available, Rec+ recurrence, Rec– recurrence free
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tumours, providing further evidence of resistance het-
erogeneity [37] where dormant tumours share similar
molecular changes, but there are likely to be a variety of
escape mechanisms that lead to acquired resistance.
In the present study, paired differential expression
analysis demonstrated that dormant tumours continue
to change under long-term treatment. Some of the iden-
tified dormancy-related pathways such as cell cycle
arrest and senescence have established roles in metasta-
sis dormancy [38], further supporting the relevance of
our clinical model, with the senescence-associated
secretory phenotype (SASP) recently suggested to regu-
late breast cancer dormancy and relapse [39]. As in
short-term responsive tumours [16], ECM organization
and degradation were significantly upregulated in dor-
mant tumours. ECM remodelling and its degradation by
Fig. 5 Validation of results using in-vitro gene expression data from resistant cell lines and proteomics analysis. a Normalised enrichment scores
of differently upregulated genes (a total of 249) between long-term treated dormant and resistant tumours calculated using single sample gene
set enrichment analysis (ssGSEA) in aromatase inhibitor-resistant cells. Scores were significantly higher (**p < 0.01, ***p < 0.001) in two aromatase
inhibitor-resistant cell lines, MCF7:2A and MCF7:5C, which were clonally derived from MCF7 breast cancer cells following long-term oestrogen
deprivation (LTED) compared with control/sensitive MCF7 cells (n = 4). Anastrozole-resistant (Ana_R) and exemestane-resistant (Exe_R) MCF7aro
cells had significantly higher scores compared with control (n = 3). b Dynamic changes in enrichment scores of LTED MCF7 cells in three different
datasets. c Scores in tamoxifen-resistant (Tam_R) and fulvestrant-resistant (Fulv_R) and drug-sensitive (control) MCF7 cells (n = 4, n = 10). d
Volcano plot showing differentially expressed proteins between long-term treated dormant and resistant tumours (p < 0.05). Some overlapping
features between transcriptomics and proteomics analysis and the most upregulated and downregulated proteins are highlighted in red and
blue, respectively. FC fold-change, sc subclone
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matrix metalloproteases (MMP) have previously been
suggested to regulate the switch between dormancy and
metastatic growth [40]. Despite histological confirmation
that each tumour sample contained at least 60% tumour,
we acknowledge that the results presented are of intact
whole tissue and potentially limited by minor variations
in tumour cellularity or the proportion of stoma which
could affect gene expression.
The most transcriptionally upregulated gene in resist-
ant tumours S100P, previously shown to be an inducer
of breast cancer metastasis correlated with decreased
survival [41]. S100P, a small calcium-binding protein
mediating Ca2+-dependent signalling pathways, has dis-
tinct functions in normal tissue and cancer, including
human embryonic development and breast cancer initi-
ation [42]. Recently, S100P hypomethylation in blood
was demonstrated to be inversely correlated with tissue
S100P expression and significantly associated with breast
cancer, implicating S100P as a potential diagnostic
marker [43]. High plasma S100P levels have also been
correlated with poor prognosis in metastatic breast can-
cer patients, with levels decreasing following treatment,
suggesting a role of S100P in dynamic monitoring of re-
sponse [44]. In the present study, S100P gene expression
and protein levels were significantly higher in resistant
tumours after long-term treatment, as well as being dif-
ferentially expressed before treatment, supporting its po-
tential role as a therapeutic target [45] and a predictive
marker.
Comparative analysis of dormant and resistant samples
after extended treatment revealed enrichment for a set
of genes with a role in DNA methylation and histone
Fig. 6 Immunohistochemical evaluation of methylation markers. a 5-methylcytosine (5-mC) and b 5-hydroxymethylcytosine (5-hmC) levels were
determined in FFPE sections from letrozole-treated samples. Representative images in dormant and resistant tumours are shown. Boxplots show
distributions of semi-quantitative intensity scores of 5-mC (*p < 0.05, ***p < 0.001; n = 5–12) and 5-hmC (***p < 0.001; n = 5–13) levels in dormant
and resistant tumours. Early-on (early, 13–120 days) and long-term (long, > 120 days) neoadjuvant aromatase inhibitor therapy with letrozole
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acetylation/deacetylation. Epigenetic alterations are rec-
ognized to occur in breast cancer. DNA methyltransfer-
ase (DNMT) and histone deacetylase (HDAC) inhibitors
have been shown to exert encouraging effects on the dis-
ease [46]. Recently, the potential role of epigenetic
changes in regulating dormancy and reactivation state
has been suggested to explain the reversible (on/off ) na-
ture of dormancy [47].
Breast cancer “CpG island methylator phenotype”
(CIMP), as revealed by genome-wide methylation ana-
lysis of metastatic breast cancers where a large number
of genes are hypermethylated, has been suggested to be
informative for metastatic potential [48]. A significant
correlation between pre-treatment global DNA methyla-
tion with neoadjuvant chemotherapy response in rectal
cancer has been reported [49]. Although DNA hypome-
thylation was the first epigenetic alteration identified in
cancer, its molecular process and effects are not yet well
understood [50]. In addition, 5-hmC levels were shown
to correlate with differentiation status, with higher levels
when more differentiated [29]. In addition, alterations in
DNA methylation in LTED MCF7 cells have been previ-
ously reported [51]. Our results provide evidence for the
loss of a global DNA methylation process in resistant tu-
mours and strengthen the case to use these models for
further study. The global decrease in 5-mC may account
for the observed reduction in 5-hmC levels since 5-mC
is converted to 5-hmC. On the other hand, at the
early-on time point, 5-hmC levels were significantly re-
duced with no significant change in 5-mC levels, sug-
gesting an independent role of the 5-hmC mark.
Hypomethylated cancer cells have been suggested to be
selected to form tumours with increased malignancy
[50]. We suggest that hypomethylation in resistant tu-
mours may reflect a de-differentiation process inducing
stem cell-like cell formation. Determining the time point
at which that hypomethylation starts, which would allow
intervention before it starts to prevent resistance to ther-
apy, needs further investigation.
The main genes significantly enriched for
epigenetics-associated pathways in the present study are
core histone (H3, H4, H2B) genes. Well-known
epigenetics-associated genes such as DNMT were not
differentially expressed in the present study. Therefore,
it might be suggested that observed changes in histone
gene levels may simply reflect the high proliferation rate
in resistant tumours since transcription of these histone
genes are replication-dependent and their mRNA levels
increase during DNA replication [52]. However, deregu-
lation of histone H2A and H2B was associated with
anthracycline resistance in breast cancer cells and re-
versed by HDAC small molecule inhibitors [53]. Further-
more, upregulation of replication-dependent core
histone proteins has been suggested to be a selective
indicator of ER-mediated MCF7 cell proliferation re-
gardless of the proliferation rate [54]. Also, observed glo-
bal loss of DNA methylation in resistant tumours
suggests dynamic regulation of gene transcription under
letrozole therapy. Therefore, histone upregulation and
alterations in epigenetic pathways observed in our study
may play a role in resistance to endocrine deprivation
therapy, rather than simply mirroring the degree of
proliferation.
Our results indicate alterations both in DNA methyla-
tion and histone modifications. HDAC inhibitors, which
have been shown to regulate DNA methylation [55],
may be successful clinically as second-line drugs alone
or in combination following oestrogen deprivation ther-
apy failure as there is growing evidence for their tumour
selective action [56, 57]. A time-dependent role for
HDACs in leukaemia has been shown [58] and may also
be critical in determining when to start HDAC inhib-
ition therapy to successfully treat tumours resistant to
oestrogen deprivation therapy. Whether or not the epi-
genetic alterations are triggers of re-awakening and if
the timely use of epigenetic drugs can prevent acquired
resistance warrants further investigation.
Conclusions
We have performed the first study of sequential tumour
samples from breast cancer patients receiving extended
neoadjuvant oestrogen deprivation therapy as a clinical
model of dormancy and acquired resistance. Our ana-
lysis suggests that molecular differences between dor-
mant and resistant tumours are initially subtle,
becoming more obvious only after extended treatment.
This study emphasizes that alterations in DNA methyla-
tion in the first months of treatment may predict which
patients will eventually develop acquired resistance.
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